» Articles » PMID: 36077492

Insights into Allosteric Mechanisms of the Lung-Enriched P53 Mutants V157F and R158L

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Sep 9
PMID 36077492
Authors
Affiliations
Soon will be listed here.
Abstract

Lung cancer is a leading fatal malignancy in humans. p53 mutants exhibit not only loss of tumor suppressor capability but also oncogenic gain-of-function, contributing to lung cancer initiation, progression and therapeutic resistance. Research shows that p53 mutants V157F and R158L occur with high frequency in lung squamous cell carcinomas. Revealing their conformational dynamics is critical for developing novel lung therapies. Here, we used all-atom molecular dynamics (MD) simulations to investigate the effect of V157F and R158L substitutions on the structural properties of the p53 core domain (p53C). Compared to wild-type (WT) p53C, both V157F and R158L mutants display slightly lesser β-sheet structure, larger radius of gyration, larger volume and larger exposed surface area, showing aggregation-prone structural characteristics. The aggregation-prone fragments (residues 249-267 and 268-282) of two mutants are more exposed to water solution than that of WT p53C. V157F and R158L mutation sites can affect the conformation switch of loop 1 through long-range associations. Simulations also reveal that the local structure and conformation around the V157F and R158L mutation sites are in a dynamic equilibrium between the misfolded and properly folded conformations. These results provide molecular mechanistic insights into allosteric mechanisms of the lung-enriched p53 mutants.

Citing Articles

Functional Investigations of p53 Acetylation Enabled by Heterobifunctional Molecules.

Chen L, Singha Roy S, Jadhav A, Wang W, Chen P, Bishop T ACS Chem Biol. 2024; 19(9):1918-1929.

PMID: 39250704 PMC: 11421428. DOI: 10.1021/acschembio.4c00438.


Molecular Insights into Macromolecules Structure, Function, and Regulation.

Yang Z, Zhao J Int J Mol Sci. 2024; 25(10).

PMID: 38791335 PMC: 11121550. DOI: 10.3390/ijms25105296.

References
1.
Emamzadah S, Tropia L, Halazonetis T . Crystal structure of a multidomain human p53 tetramer bound to the natural CDKN1A (p21) p53-response element. Mol Cancer Res. 2011; 9(11):1493-9. DOI: 10.1158/1541-7786.MCR-11-0351. View

2.
Lei J, Cai M, Shen Y, Lin D, Deng X . Molecular dynamics study on the inhibition mechanisms of ReACp53 peptide for p53-R175H mutant aggregation. Phys Chem Chem Phys. 2021; 23(40):23032-23041. DOI: 10.1039/d1cp03094a. View

3.
Navalkar A, Ghosh S, Pandey S, Paul A, Datta D, Maji S . Prion-like p53 Amyloids in Cancer. Biochemistry. 2019; 59(2):146-155. DOI: 10.1021/acs.biochem.9b00796. View

4.
Peters M, Yang Y, Wang B, Fusti-Molnar L, Weaver M, Merz Jr K . Structural Survey of Zinc Containing Proteins and the Development of the Zinc AMBER Force Field (ZAFF). J Chem Theory Comput. 2010; 6(9):2935-2947. PMC: 2941202. DOI: 10.1021/ct1002626. View

5.
Strano S, Fontemaggi G, Costanzo A, Rizzo M, Monti O, Baccarini A . Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem. 2002; 277(21):18817-26. DOI: 10.1074/jbc.M201405200. View